Close

GPC1

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

Product List Background Anti-GPC1 CAR-T Services Anti-GPC1 CAR-T In Vitro Assay ServicesAnti-GPC1 CAR-T In Vivo Assay Services

Product List

Our team of experts has extensive experience in CAR-T cell development and comprehensive anti-GPC1 CAR-T products and services for our clients.

Background

Glypican-1 (GYC1) is a member of the GRIPS family of proteoglycans. Cell surface heparan sulfate proteoglycans are composed of a membrane-associated protein core substituted with a variable number of heparan sulfate chains. Members of the glypican-related integral membrane proteoglycan family (GRIPS) contain a core protein anchored to the cytoplasmic membrane via a glycosyl phosphatidylinositol linkage. These proteins may play a role in the control of cell division and growth regulation. GYC1 has been shown to interact with several growth factors, including fibroblast growth factor (FGF), hedgehog, and Wnt proteins, and to regulate their signaling activities.

Associated Diseases

Liver cancer

Melanoma

Pancreatic cancer

Anti-GYC1 CAR-T Services

Anti-GYC1 CAR-T In Vitro Assays

Anti-GYC1 CAR-T Expression Test

At Creative Biolabs, we offer several methods to detect CAR expression, including flow cytometry, qPCR, and WB. Protein L and anti-Fab antibodies are common tools for the detection and quantification of anti-GPC1 CAR.

Fig.1 Flow cytometry analysis of CAR expression by detection of hEGFRt expression. (Li, et al., 2023)Fig.1 Flow cytometry analysis of CAR expression by detection of hEGFRt expression.1

Anti-GYC1 CAR-T Cytokine Release Test

Our comprehensive cytokine release test services detect a wide range of cytokines, including IL-2, TNF-α, and IFN-γ.

Fig.2 The expression of cytokines in GYC1 CAR-T cells co-cultured with T3M4 cells. (Li, et al., 2023)Fig.2 The expression of cytokines in GYC1 CAR-T cells co-cultured with T3M4 cells.1 The various constructs showed different levels of cytokine release (IFN-γ and IL-2) in the co-cultured supernatants.

Anti-GYC1 CAR-T In Vitro Cytotoxicity Assay

We use some common methods for evaluating the cytotoxicity of anti-GYC1 CAR-T cells, including a bioluminescence-based assay, LDH release assay, and flow cytometry assay.

Fig.3 The cytotoxic potential of anti-GYC1L CAR-T against GYC1+cell lines (high GPC1-expressing 2B9 cells and low GPC1-expressing T3M4 cells). (Li, et al., 2023)Fig.3 The cytotoxic potential of anti-GYC1L CAR-T against GYC1+cell lines (high GPC1-expressing 2B9 cells and low GPC1-expressing T3M4 cells).1 GYC1L CAR-T cells exhibited antigen-specific cytotoxicity against GYC1+ cells and showed different cytotoxic potential to T3M4 cells.

Anti-GYC1 CAR-T In Vivo Assays

Anti-GYC1 CAR-T Cell Therapy Animal Models

At our lab, we offer a range of in vivo anti-GYC1L CAR-T cell therapy testing mouse models, including xenograft, humanized, syngeneic, and transgenic models. These animal models play a crucial role in the development and evaluation of CAR-T therapies.

Fig.4 Experimental schematic of CAR-T therapy xenograft mouse model. (Li, et al., 2023)Fig.4 Experimental schematic of CAR-T therapy xenograft mouse model.1

Efficacy Test of Anti-GYC1 CAR-T

Creative Biolabs provides services to evaluate the therapeutic efficacy of anti-GPC1 CAR T cells in vivo. In vivo antitumor activity of anti-GPC1 CAR T cells against GPC1+ cancer cells is assessed by the detection of the tumor growth and survival of mice.

Fig.5 In vivo evaluation of the antitumor activity of GYC1 CAR-T in a xenograft mouse model. (Li, et al., 2023)Fig.5 In vivo evaluation of the antitumor activity of GYC1 CAR-T in a xenograft mouse model.1 The results showed that IgG4H-CD28TM CAR T cells rapidly eliminated T3M4 tumor cells in mice.

Toxicity Evaluation Anti-GPC1 CAR-T

Our scientists have rich experience in the evaluation of the toxicity of CAR-T cells. We provide various CAR-T toxicity study services including tumorigenicity study, on-target toxicity, and off-target toxicity.

Reference

  1. Li, Nan, et al. "The IgG4 hinge with CD28 transmembrane domain improves VHH-based CAR T cells targeting a membrane-distal epitope of GPC1 in pancreatic cancer." Nature Communications 14.1 (2023): 1986.
  • CAR Vector Products

  • AbTCR Vector Products

  • CAR Cell Products

  • CAR Viral Particles

  • DMAb

  • CAR mRNA

Loading...
  • Target Species:
  • Antibody Clone:
  • Antibody Host:
  • Receptor Construction:
  • Vector Type:
  • Targeting Cell Type:
  • CAR Vector Type:
CAT Product Name Target Species Antibody Clone Antibody Host Receptor Construction Vector Type Targeting Cell Type CAR Vector Type Inquiry & Datasheet
XS-0822-LX105 Anti-GPC1 (X8X105) h(CD28-41BB-CD3ζ) CAR, pCDCAR1 Human X8X105 Mouse scFv-CD28-41BB-CD3ζ Lentiviral vector T cell   Add to Cart   Datasheet
XS-0822-LX106 Anti-GPC1 (X8X106) h(CD28-41BB-CD3ζ) CAR, pCDCAR1 Human X8X106 Mouse scFv-CD28-41BB-CD3ζ Lentiviral vector T cell   Add to Cart   Datasheet
XS-0822-LX119 Anti-GPC1 (X8X119) h(CD28-41BB-CD3ζ) CAR, pCDCAR1 Human X8X119 Mouse scFv-CD28-41BB-CD3ζ Lentiviral vector T cell   Add to Cart   Datasheet
XS-0822-LX283 Anti-GPC1 (X8X96) h(CD28-OX40-CD3ζ) CAR, pCDCAR1 human X8X96 Humanized scFv-CD28-OX40-CD3ζ Lentiviral vector T cell   Add to Cart   Datasheet
XS-0822-LX284 Anti-GPC1 (X8X97) h(CD28-OX40-CD3ζ) CAR, pCDCAR1 human X8X97 Humanized scFv-CD28-OX40-CD3ζ Lentiviral vector T cell   Add to Cart   Datasheet
XS-0822-LX285 Anti-GPC1 (X8X98) h(CD28-OX40-CD3ζ) CAR, pCDCAR1 human X8X98 Humanized scFv-CD28-OX40-CD3ζ Lentiviral vector T cell   Add to Cart   Datasheet
XS-0822-LX286 Anti-GPC1 (X8X99) h(CD28-OX40-CD3ζ) CAR, pCDCAR1 human X8X99 Humanized scFv-CD28-OX40-CD3ζ Lentiviral vector T cell   Add to Cart   Datasheet
XS-0822-LX470 Anti-GPC1 (X8X96) h(ICOS-41BB-CD3ζ) CAR, pCDCAR1 human X8X96 Humanized scFv-ICOS-4-1BB-CD3ζ Lentiviral vector T cell   Add to Cart   Datasheet
XS-0822-LX471 Anti-GPC1 (X8X97) h(ICOS-41BB-CD3ζ) CAR, pCDCAR1 human X8X97 Humanized scFv-ICOS-4-1BB-CD3ζ Lentiviral vector T cell   Add to Cart   Datasheet
XS-0822-LX472 Anti-GPC1 (X8X98) h(ICOS-41BB-CD3ζ) CAR, pCDCAR1 human X8X98 Humanized scFv-ICOS-4-1BB-CD3ζ Lentiviral vector T cell   Add to Cart   Datasheet
XS-0822-LX473 Anti-GPC1 (X8X99) h(ICOS-41BB-CD3ζ) CAR, pCDCAR1 human X8X99 Humanized scFv-ICOS-4-1BB-CD3ζ Lentiviral vector T cell   Add to Cart   Datasheet
XS-0822-LX474 Anti-GPC1 (X8X100) h(ICOS-41BB-CD3ζ) CAR, pCDCAR1 Human X8X100 Mouse scFv-ICOS-4-1BB-CD3ζ Lentiviral vector T cell   Add to Cart   Datasheet
XS-0822-LX475 Anti-GPC1 (X8X101) h(ICOS-41BB-CD3ζ) CAR, pCDCAR1 Human X8X101 Mouse scFv-ICOS-4-1BB-CD3ζ Lentiviral vector T cell   Add to Cart   Datasheet
XS-0822-LX476 Anti-GPC1 (X8X102) h(ICOS-41BB-CD3ζ) CAR, pCDCAR1 Human X8X102 Mouse scFv-ICOS-4-1BB-CD3ζ Lentiviral vector T cell   Add to Cart   Datasheet
XS-0822-LX477 Anti-GPC1 (X8X103) h(ICOS-41BB-CD3ζ) CAR, pCDCAR1 Human X8X103 Mouse scFv-ICOS-4-1BB-CD3ζ Lentiviral vector T cell   Add to Cart   Datasheet
XS-0822-LX478 Anti-GPC1 (X8X104) h(ICOS-41BB-CD3ζ) CAR, pCDCAR1 Human X8X104 Mouse scFv-ICOS-4-1BB-CD3ζ Lentiviral vector T cell   Add to Cart   Datasheet
XS-0822-LX479 Anti-GPC1 (X8X105) h(ICOS-41BB-CD3ζ) CAR, pCDCAR1 Human X8X105 Mouse scFv-ICOS-4-1BB-CD3ζ Lentiviral vector T cell   Add to Cart   Datasheet
XS-0822-LX480 Anti-GPC1 (X8X106) h(ICOS-41BB-CD3ζ) CAR, pCDCAR1 Human X8X106 Mouse scFv-ICOS-4-1BB-CD3ζ Lentiviral vector T cell   Add to Cart   Datasheet
XS-0822-LX481 Anti-GPC1 (X8X107) h(ICOS-41BB-CD3ζ) CAR, pCDCAR1 Human X8X107 Mouse scFv-ICOS-4-1BB-CD3ζ Lentiviral vector T cell   Add to Cart   Datasheet
XS-0822-LX482 Anti-GPC1 (X8X108) h(ICOS-41BB-CD3ζ) CAR, pCDCAR1 Human X8X108 Mouse scFv-ICOS-4-1BB-CD3ζ Lentiviral vector T cell   Add to Cart   Datasheet
XS-0823-LX62 Anti-hGPC1 (1.4) ICD(CD28-OX40-CD3ζ) CAR-MA, pAd5f35 Vector Human 1.4 Adenoviral vectors   Add to Cart   Datasheet
Unable to find the desired product? Explore the Filter Options at the top of the list.
Key Updates
Newsletter NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER
New Solution NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION
NOVEL SOLUTION NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY
NEW TECHNOLOGY NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION
Receive our latest news and insights.